RET-Targeted Molecular Imaging Probes in Prostate Cancer

Más betegség

• Patients without prostate cancer.
• Fever with body temperature above 38°C or clinically evident active infection that could affect the trial.
• Uncontrolled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg).
• Significant cardiovascular abnormalities (e.g., myocardial infarction, superior vena cava syndrome, grade 2 or higher heart disease before enrollment, or heart disease that increases the risk of ventricular arrhythmia as judged by the investigator).
• Third-degree atrioventricular block or symptomatic sick sinus syndrome.
• Patients who cannot complete the PET examination due to disease progression.

Laborértékek

• Cardiac, pulmonary, hepatic, or renal function assessed as unsuitable for the examination (e.g., organic heart disease or arrhythmia; abnormal pulmonary function such as FVC, FEV1, FEV1/FVC, DLCO, or DLCO/VA outside the normal range with ventilatory disorders; abnormal liver function with AST, ALT, or ALP more than 1 times the upper limit of the reference range; total/direct bilirubin above normal or total protein, albumin, and globulin below normal; abnormal renal function such as hematuria or proteinuria, or creatinine, urea, or uric acid above normal values).
• History of arrhythmia (multifocal ventricular premature beats, bigeminy, trigeminy, or congenital long QT syndrome).

Egyéb

• Abnormal coagulation function (PET/CT involves venous injection; normal coagulation must be ensured).
• Tachycardia or uncontrolled atrial fibrillation, symptomatic or requiring treatment (CTCAE grade 3), or asymptomatic sustained tachycardia.
• Presence of left bundle branch block.
• Patients too ill to undergo further evaluation and treatment.

• Male patients aged 45-80 years.
• Diagnosed with conventional prostatic adenocarcinoma or neuroendocrine prostate cancer (NEPC) by clinical data, serum markers, and pathology (biopsy); patients with no other neuroendocrine tumors or related diseases and no history of acute infection or acute trauma.
• Patients with newly diagnosed disease will be enrolled before receiving specific treatment (ADT, chemotherapy, second-generation androgen receptor inhibitors, etc.) whenever possible; patients with recurrent disease will be enrolled as soon as possible.
• Able to cooperate in the observation of adverse events and efficacy.
• Patients with suspected NEPC based on positive serum neuroendocrine markers (SYP/CHGA/NSE), or confirmed NEPC by biopsy histopathology with positive neuroendocrine marker immunohistochemistry (SYP/CHGA/NSE).
• Capable of undergoing pathological examination to confirm the diagnosis; willing to provide informed consent and able to accept follow-up.
• The patient or his legally authorized representative signs the written informed consent form.